The pharma giant has completed the acquisition of TeneoTwo, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma. AstraZeneca will
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who
Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) darolutamide in
Zealand Pharma has given formal notice to Nasdaq of the company’s intention to voluntarily remove its American Depositary Shares (ADSs) from listing on the New York-based Nasdaq Global Select Market.
Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who
For the past 14 years Jutta Heix has been an important cog in the wheel in accelerating the development of new cancer treatments and diagnostics – connecting and helping innovators
Valo Therapeutics has announced the exclusive licensing of intellectual property rights (IPR) from the University of Helsinki for the institution’s innovative PeptiCHIP technology. Following further validation by ValoTx, and the
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with
The FDA has granted 510(k) clearance for the product DiviTumTKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients. “We
Iconovo has received a grant of USD 883,800 from the Bill & Melinda Gates Foundation. The grant work plan is focused on the development of a low-cost device that can
The European Commission (EC) has extended the marketing authorization for the company’s smallpox vaccine, IMVANEX to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows
Sometimes a simple event can have far-reaching consequences, as in the case of Princeton University professor Dr. David MacMillan, when a leaky roof led to an award-filled career in chemistry.
One of the best things with being a scientist, according to Nobel Laureate Benjamin List, is that you discover things that nobody else has seen before – and, following his
The Novo Nordisk Foundation (NNF) has awarded a 195 million DKK grant for establishing a national, brickless Danish Diabetes and Endocrine Academy (DDEA) with an executive office based at Odense
The COVID-19 pandemic
Sweden’s Minister of Health and Social Affairs, Lena Hallengren, has officially inaugurated Valneva Sweden’s new COVID-19 vaccine manufacturing facility, the first and only one of its kind in Sweden. “The
Two ongoing research studies funded by NordForsk are providing new knowledge about COVID-19 related to pregnancy and mental health. The Nordic countries have similar welfare systems, access to high-quality health
Bavarian Nordic has provided an update on the Phase 3 development of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The upcoming Phase 3 trial has been redesigned to include
New research from Karolinska Institutet shows that a booster shot of mRNA vaccine to individuals who have received two doses of inactivated vaccine offers the same level of protection against
Several months after COVID-19, one is still at an increased risk of blood clot and bleeding, shows research from Umeå University. The researchers analyzed all COVID-19 cases in Sweden from the
Drug and device development
Bio-Me today has become part of the Medicen Microbiome Drug Metabolism working group, an international initiative by leading academic, pharma and institutions to address the need for better understanding of
BioInvent International has announced treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors. The first-in-human
Mendus has announced the publication of in vivo data demonstrating significant anti-tumor synergies between the company’s allogeneic dendritic cell-based immune primer program ilixadencel and immune checkpoint inhibition via CTLA-4 blockade
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation
Pila Pharma has announced that the preclinical toxicological three-month studies of the active substance XEN-D0501 has begun. Pila Pharma is, as previously announced, preparing a clinical phase 2b study of
Profile
Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real
In a new job
In her new role as Chief Executive Officer at Medicon Valley Alliance, Anette Steenberg aims to zoom in on the strongholds of the region as well as strengthening the framework
Valur Ragnarsson has been appointed as Chairman of the Board by Coripharma’s Board of Directors. Valur is a pharmaceutical executive with a solid track record spanning over 30 years, driving
Orion Corporation’s Board of Directors has appointed Liisa Hurme as President and CEO of Orion Corporation and the Chair of the Executive Management Board of the Orion Group as of
Careers
Ann-Britt Önnered and Linda Jervelius manage Quality Assurance at a microbiology laboratory and share their insights about maintaining a secure and hygienic laboratory environment, a crucial part of lab life.
Read the latest issue of our magazine!
No 02 2022 // This issue includes in-depth articles about successful company growth within life sciences. What lessons can we learn from the journeys, progress, setbacks and challenges of other Nordic companies? What perspectives and advice can the region’s investors and business advisors provide?
In addition, Jutta Heix, Head of International Affairs at Oslo Cancer Cluster, describes how she is accelerating the development of new cancer treatments and diagnostics – connecting and helping innovators and putting Norwegian oncology on the global map, and Bengt Mattson, special adviser at Lif, writes about health in the shadow of war. We take a closer look at four different career choices within drug discovery; their daily tasks, what challenges they encounter and what drives them in their different roles.
This, and much more, in our latest issue – out now!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region. It connects life science and healthcare industry leaders with international investment and
Since its inception in 2013, NLSDays has nurtured a community of people from the world of life science, and created a unique place to do business. This annual event offers an informal
This event is scheduled as a 3 day in-person event in Leipzig, October 24-26, and a 3 day virtual event, November 2-4. This year the event will be held in
At Outsourcing in Clinical Trials and Clinical Trial Supply Nordics the pharmaceutical, biotechnology, and medical device communities need to come together and discuss strategies for operational success in clinical trials.
The latest research news from the Nordic region
Science Article
Turning down the thermostat seems to make it harder for cancer cells to grow, according to a study in mice by researchers at Karolinska Institutet. The study, published in the
The Nobel Prize in Chemistry 2021 shed light on a simple, sustainable and smart molecular building tool that has had a great impact on pharmaceutical production. The Royal Swedish Academy
The European Patent Office (EPO) has honoured Hungarian-American researcher Katalin Karikó with the European Inventor Award 2022 in the category “Lifetime achievement”, for her seminal work in developing modified messenger
Dr Martin Oeggerli at Micronaut GmBH, Basel, Switzerland, is this year’s winner of the Lennart Nilsson Award. Martin Oeggerli holds a PhD in medical molecular biology. Since 2005, he works
For the first time, scientists have succeeded in producing brain scans that detect the presence of alpha-Synuclein. The detection trial was conducted by Dr Oskar Hansson, Professor of Neurology at
Solna District Court is convicting the surgeon Paolo Macchiarini for one case of causing bodily injury, serious crime. Macchiarini is found not guilty in two other cases and convicted to
Nordic Life Science
The latest clinical trials
BioInvent International has announced treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors. The first-in-human
Mendus has announced the publication of in vivo data demonstrating significant anti-tumor synergies between the company’s allogeneic dendritic cell-based immune primer program ilixadencel and immune checkpoint inhibition via CTLA-4 blockade
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation
Pila Pharma has announced that the preclinical toxicological three-month studies of the active substance XEN-D0501 has begun. Pila Pharma is, as previously announced, preparing a clinical phase 2b study of
Ultimovacs has announced the completed recruitment of 154 patients in the INITIUM trial. INITIUM is Ultimovacs’ Phase II clinical trial of its universal cancer vaccine UV1 in combination with the
The US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for the combination of TG01 and QS-21 STIMULON. The IND is a major milestone for
Immunovia has announced results from the PanFAM-1 study, a prospective, multi-center, investigational study, designed to assess the performance of the IMMray PanCan-d test in early detection of pancreatic ductal adenocarcinoma
AlzeCure Pharma has completed the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, with a focus on Alzheimer’s disease. Data show that
BioInvent International and Transgene have jointly announced positive progress and safety data of the ongoing Phase 1/2a trial evaluating BT-001 in patients with solid tumors, including melanoma. The initial data
Sign up to our newsletter